公司资料
Acumen Pharmaceuticals 股价、新闻与催化剂
- 股票代码:
- ABOS
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
2.66 USD (-0.37%)
收盘价
最后更新: 2026年8月17日
171M USD
市值
股价为何变动
As of Aug 17, 2026, ABOS closed down 0.37% at $2.66. No new same-company headline was identified in the current news window.
公司概览
Alzheimer’s Disease Antibody Company
Acumen Pharmaceuticals develops therapies targeting soluble amyloid-beta oligomers, which are believed to contribute directly to synaptic dysfunction in Alzheimer’s disease.
Sabirnetug
Sabirnetug is a monoclonal antibody designed to selectively bind toxic amyloid-beta oligomers while limiting interaction with monomers and plaques.
Enhanced Brain Delivery
Acumen is also developing an enhanced brain-delivery platform intended to improve central nervous system exposure of future biologics.
未来催化剂
- Topline results from the Phase 2 ALTITUDE-AD study of sabirnetug are expected in late 2026.
- An IND filing for the lead enhanced brain-delivery candidate is targeted for mid-2027.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。